TRIAL DETAIL

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Drug:
Trial Name:
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 10/01/2007
Age of Trial (yrs) 14.7
Treatment Phase:
Gleevec-resistant
Drug Category:
HSP90 inhibitor
Strategy:
Destroy KIT
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
9090-01
Sponsor:
Synta Pharmaceuticals
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
IV Intravenous
Trial Notes:
STA-9090 is a novel Hsp90 inhibitor. Based on pre-clinical data, it appears to be 10 to 100 times more potent than the geldanamycin family of Hsp90 inhibitors (such as 17AAG). Because of the increased potency, it appears to be able to inhibit a broader range of Hsp90 client proteins.
This phase I trial will give STA-9090 twice a week for 3 weeks followed by a one week drug holiday. A future phase I trial giving STA-9090 once a week for 3 weeks with a one week drug holiday is planned.

Trial Links

Trial Results

 
 

Drug Information

Press release - Synta initiates phase 2 clinical trial of STA-9090 in GIST following failure of Gleevec and Sutent
 
Synta drug information page
 
Premeire Oncology STA-9090 trial information
 
Results differentiate STA-9090 in Hsp90 inhibitor class and show activity in erlotinib-resistant lung cancer models
 
Reuters article about Synta starting a third phase I trial
 
Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
 
Reuters article about Synta starting second phase I trial
 
CTOS 2009 Poster: In Vitro and In Vivo Efficacy of the Novel Hsp90 Inhibitor STA-9090 (PDF)
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
4100 John R
Detroit
MI
48201
USA
55 Fruit Street
Boston
MA
02114
USA
330 Brookline Ave.
Boston
MA
02215
USA
10945 Le Conte Ave.
Los Angeles
CA
90095
USA